Design and endpoints of clinical and translational trials in advanced colorectal cancer. A proposal from GROUP Español Multidisciplinar en cancer digestivo (GEMCAD)

Reviews on Recent Clinical Trials

Volumn 6, Issue 2, 2011, Pages 158-170

  Carrera, Gemma ^a   Garcia Albeniz, Xabier ^a   Ayuso, Juan Ramón ^a   Aparicio, Jorge ^b   Castells, Antoni ^a   Codony Servat, Jordi ^a   Feliu, Jaime ^c   Fuster, David ^a   Gallego, Rosa ^a   Pagés, Mario ^a   Torres, Ferran ^a   Maurel, Joan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Advanced colorectal cancer; Endpoints; Surrogate markers

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GADOLINIUM; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ADVANCED CANCER; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRYOABLATION; DRUG MEGADOSE; ECHOGRAPHY; HUMAN; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; MONOTHERAPY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME;

CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN;

EID: 79953872246     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488711795177868     Document Type: Review

References (106)

1. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a metaanalysis. Meta-Analysis Group in Cancer. Lancet 2000; 356: 373-78.
2. Louvet C, de Gramont A, Tournigand C, et al. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 2001; 91: 2033-38.
3. Johnson KR, Ringland C, Stokes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: A Meta-analysis. Lancet Oncol 2006; 7: 741-6.
4. Tang PA, Bentzen SM, Chen EX, Liu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: Literaturebased analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007; 25: 4562-68.
5. Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007; 25: 5218-24.
6. Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JPA. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 2007; 7: 70281-4.
7. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer of Collaborative group. BMJ 2000; 321: 531-5.
8. Gollub M, Schartz L, Akhurst T. Update on colorectal cancer imaging. Radiol Clin N Am 2007; 45: 85-118.
9. Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastasis from cancers of the gastrointestinal tract by using non-invasive imaging methods (US, CT, Mrimaging, PET): a metaanalysis. Radiology 2002; 224: 748-56.
10. Bipat S, van Leeuwen M, Comans E, et al. Colorectal liver metastasis: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 2005; 237: 123-31.
11. Schima W, Kulinna C, Langenberger H, Ba-Ssalamah A. Liver metastasis of colorectal cancer: US, CT or MRI? Cancer Imaging 2005; 5: 149-155.
12. Mainenti P, Mancini M, Mainolfi C, et al. Detection of colo-rectal liver metastasis: prospective comparison of contrast enhanced US, multidetector CT, PET/CT and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents. Abdom Imaging 2010; 35: 511-21.
13. Muntean V, Oniu T, Lungoci C, et al. Staging laparoscopy in Digestive Cancers. J Gastrointestinal Liver Dis 2009; 18: 189-95.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
16. Moskowitz CS, Jia X, Schwartz LH, Gonen M. A simulation study to evaluate the impact of the number of lesions measured on response assessment. Eur J Cancer 2009; 45: 300-10.
17. Glazer GM, Gross BH, Quint LE, Francis IR, Bookstein FL, Orringer MB. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. AJR Am J Roentgenol 1985; 144: 261-65.
18. Steinkamp HJ, Hosten N, Richter C, Schedel H, Felix R. Enlarged cervical lymph nodes at helical CT. Radiology 1994; 191: 795-798.
19. Schwartz LH, Bogaerts J, Ford R, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 2009; 45: 261-67.
20. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302: 2338-44.
21. Sargent DJ, Rubinstein L, Schwartz L, et al. Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer 2009; 45: 290-9.
22. Rkein AM, Harrigal C, Friedman AC, Persky D, Krupinski E. Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis). Acad Radiol 2009; 16: 181-6.
23. Kim YS, Rhim H, Lim HK. Imaging after radiofrequency ablation of hepatic tumors. Semin Ultrasound CT MR 2009; 30: 49-66.
24. Ford R, Schwartz L, Dancey J, et al. Lessons learned from independent central review. Eur J Cancer 2009; 45: 268-74.
25. Truant S, Huglo D, Hebbar M, Ernst O, Steinling M, Pruvot FR. Prospective evaluation of the impact of [(18)F]fluoro-2-deoxy-Dglucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 2005; 92: 362-9.
26. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004; 240: 1027-34.
27. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240: 438-47.
28. Adie S, Yip C, Chu F, Morris DL. Resection of liver metastases from colorectal cancer: does preoperative chemotherapy affect the accuracy of PET in preoperative planning? ANZ J Surg 2009; 79: 358-61.
29. Akhurst T, Kates TJ, Mazumdar M, et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 2005; 23: 8713-16.
30. Small RM, Lubezky N, Shmueli E, et al. Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol 2009; 99: 93-8.
31. Vriens D, van Laarhoven HW, van Asten JJ, et al. Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate. J Nucl Med 2009; 50: 1777-84.
32. de Geus-Oei LF, van Laarhoven HW, Visser EP et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 2008; 19: 348-52.
33. Byström P, Berglund A, Garske U, et al. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol 2009; 20: 1057-61.
34. Sorbye H, Kohne CH, Sergeant DJ, Grimelius B. Patients characteristics and stratification in medical treatment studies for metastatic colorectal cancer: A proposal for standardization of patients characteristic reporting and stratification. Ann Oncol 2007; 18: 1666-72.
35. Sargent DJ, Kohne CH, Sanoff HK, et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine-first-line treatments trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 2009; 12: 1948-55.
36. Kohne CH, Cunningham D, Di CF, et al. Clinical determinants of survival in patients with 5-flurouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-17.
37. Mitry E, Douillard JY, Van Cutsem E, et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004; 15: 1013-17.
38. Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009; 20: 1964-70.
39. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-16.
40. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment of bevacizumab. J Natl Cancer Inst 2005; 97: 981-9.
41. V Cutsem E, Lang I, Folprecht M, et al. Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. ASCO 2010.
42. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: Results from the MRC Trial. J Clin Oncol 2009; 27: 5931-7.
43. Lorenz M, Muller HH, Schramm H. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg 1998; 228: 756-62.
44. Kemeny MM, Adak S, Gray B. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002; 20: 1499-505.
45. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26: 4906-11.
46. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 2039-48.
47. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 473-81.
48. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet 2000; 355: 1041-47.
49. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 2000; 343: 905-14.
50. Giacchetti S, Perpoint B, Zidani R. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracilleucovorin as first-line treatment of metastatic colorectal cancer. Clin Oncol 2000; 18: 136-47.
51. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
52. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly highdose 24h5FU infusion/FA +oxaliplatin (OXA) in advanced colorectal cancer (ACRC). Proc ASCO 2002 (abstr 512).
53. Cunningham D, Sirohi B, Pluzanska A, et al. Two different firstline 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol 2009; 20: 244-50.
54. Maiello E, Gebbia V, Giuliani F, et al., on behalf of the Southern Italy Oncology Group (GOIM). 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: A multicenter randomised phase II study of the Southern Italy Oncology Group. Ann Oncol 2000; 11: 1045-51.
55. Köhne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856-65.
56. Hospers GA, Schaapveld M, Nortier JW, et al. Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in firstline treatment of advanced colorectal cancer. Ann Oncol 2006; 17: 443-9.
57. Seymour MT, Maughan TS, Ledermann JA, et al. FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143-52.
58. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370: 135-42.
59. Gennatas C, Papaxoinis G, Michalaki V, et al. A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma. J Chemother 2006; 18: 538-44.
60. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-37.
61. Comella P, Massidda B, Filippelli G, et al. Oxaliplatin plus highdose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial. Ann Oncol 2005; 16: 878-86.
62. Colucci G, Gebbia V, Paoletti G, et al. Gruppo Oncologico Dell'Italia Meridionale. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23: 4866-75.
63. Kalofonos HP, Aravantinos G, Kosmidis P, et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as firstline treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol 2005; 16: 869-77.
64. Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial J Clin Oncol 2006; 24: 3347-53.
65. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
66. Martoni AA, Pinto C, Di Fabio F, et al. Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). Eur J Cancer 2006; 42: 3161-8.
67. Díaz-Rubio E, Tabernero J, Gómez-España A, et al. Spanish Cooperative Group for the Treatment of Digestive Tumors. Phase III study of capecitabine plus oxaliplatin compared with continuousinfusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25: 4224-30.
68. Porschen R, Arkenau HT, Kubicka S, et al. AIO Colorectal Study Group. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25: 4217-23.
69. Cassidy J, Clarke S, Di{dotless}́az-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26: 2006-2012.
70. Ducruex M, Bennouna J, Hebbar M, et al. Capecitabine plus oxaliplatin (XELOX) vs 5-Fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic cancer. Int J Cancer.
71. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26: 3523-9.
72. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stopand-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol 2006; 24: 394-400.
73. Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27: 5727-33.
74. Adams R, Wilson RH, Seymour MT, et al. Intermittent versus continuous oxaliplatin-based combination chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): First analysis of quality of life (QL) and updated efficacy results from the CRC COIN trial. Proc ASCO GI 2010; 403.
75. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med 2004; 350: 2335-42.
76. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-705.
77. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-5.
78. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-9.
79. Tebbutt N, Wilson K, V. Gebski V, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28: 3191-8.
80. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-71.
81. Borner M, Koeberle D, Von Moos R, et al. Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 2008; 19: 1288-92.
82. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17.
83. Maughan TS, Adams R, Smith CG, et al. COIN Trial Management Group and Trial Investigators. Oxaliplatin and fluoropyrimidine chemotherapy plus or minus cetuximab: The effect of infusional 5-FU or capecitabine on the outcomes of the MRC COIN trial in advanced colorectal cancer (ACRC). ASCO GI 2010; 402.
84. Douillard JY, Siena S, Cassidy J, et al. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. J Clin Oncol 2010; 28: 4697-705.
85. Tveit K, Guren T, Grimelius B, et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first line treatment of metastatic colorectal cancer: The Nordic VII study (NCT00145314), by the Nordic colorectal cancer. ESMO Proc 2010, LBA20.
86. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006; 94: 798-805.
87. Falcone A, Ricci S, Brunetti I, et al. Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-6.
88. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27: 672-80.
89. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-72.
90. Mandrekar SJ, Sargent DJ. Clinical trials designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 2009; 27: 4027-34.
91. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: Results from the MRC Trial. J Clin Oncol 2009; 27: 5931-37.
92. Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007; 25: 1247-54.
93. Cecchin E, Innocenti F, D'Andrea M, et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 2009; 27: 2457-65.
94. Prenen H, De Schutter J, Jacobs B, et al. PI3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009; 15: 3184-8.
95. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27: 2622-9.
96. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27: 5924-30.
97. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-7.
98. Scartozzi M, Mandolesi A, Giampieri R, et al. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer 2010 127: 1941-7.
99. Horndler C, Gallego R, Garcia-Albeniz X, et al. Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (p-IGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab. A GEMCAD study. Cancer Biol Ther 2010 (in press).
100. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
101. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
102. Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009; 27: 5068-74.
103. Nadal C, Maurel J, Gallego R, et al. FAS/FAS ligand ratio: A marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer. Clin Cancer Res 2005; 11: 4770-4774.
104. Gallego R, Codony-Servat J, Garcia-Albeniz X, et al. Serum IGF-I, IGFBP-3 and matrix metalloproteinase-7 levels in acquired chemoresistance in advanced colorectal cancer. Endocr Relat Cancer 2009; 16: 311-7.
105. Mutsaers AJ, Francia G, Man S, et al. Dose-dependent increases in circulating TGF-a and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. Clin cancer Res 2009; 15: 2397-405.
106. Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fluouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2009; 28: 453-59.